<DOC>
	<DOCNO>NCT00707889</DOCNO>
	<brief_summary>To determine effect ABT-869 plus mFOLFOX6 compare bevacizumab plus mFOLFOX6 disease progression advance colorectal cancer .</brief_summary>
	<brief_title>Phase 2 Study ABT-869 Combination With mFOLFOX6 Versus Bevacizumab Combination With mFOLFOX6 Treat Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Subject must &gt; /= 18 year age . Subject ( male female ) must diagnose adenocarcinoma colon rectum . Subject must metastatic disease locally recurrent disease amenable surgical resection curative intent . Subject must receive one prior chemotherapy regimen contain irinotecan fluoropyrimidine locally recurrent metastatic colon rectal cancer . Subject experience progressive disease follow previous antitumor treatment . Subject may receive prior adjuvant treatment colorectal cancer . Subject measurable disease RECIST criterion ( randomize portion ) . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 . Subject must adequate bone marrow , renal hepatic function . Subject must Partial Thromboplastin Time ( PTT ) &lt; 1.5 x Upper Limit Normal ( ULN ) International Normalized Ratio ( INR ) &lt; 1.5 . Subject receive one prior therapy metastatic setting . Leadin Cohort : The subject may receive one prior therapy metastatic setting . Subject receive cytotoxic chemotherapy within 21 day prior Study Day 1 . Subject receive noncytotoxic , anticancer therapy within 21 day within period define 5 half life whichever short , prior Study Day 1 . Subject recover less equal Grade 1 clinically significant adverse effects/toxicities previous therapy . Subject receive prior treatment tyrosine kinase inhibitor target VEGF PDGF . Subject receive prior treatment oxaliplatin metastatic setting . Leadin cohort : Prior treatment oxaliplatin allow provide neuropathy result oxaliplatin treatment resolve less equal Grade 1 . Subject major surgery within 28 day Study Day 1 . Subject radiotherapy within 14 day Study Day 1 . Subject history hypersensitivity recombinant murine monoclonal antibody , oxaliplatin platinumcontaining compound , fluorouracil , folinic acid . Subject know intolerance bevacizumab . Subject untreated brain meningeal metastasis . Subject receive therapeutic anticoagulation therapy . Subject history of/or currently exhibit clinically significant cancer relate event bleed . Subject currently exhibit symptomatic persistent , uncontrolled hypertension . Subject history myocardial infarction , stroke , transient ischemic attack within six month Study Day 1 . History another active cancer within past 5 year except cervical cancer situ , situ carcinoma bladder , squamous cell basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>